1、1 On the Cusp of a CureIs Asia Pacific Ready for the Precision Era?AustraliaL.E.K.Consulting is a registered trademark of L.E.K.Consulting LLC.All other products and brands mentioned in this document are properties of their respective owners.2025 L.E.K.Consulting LLC1 L.E.K.Consulting|On the Cusp of
2、 a CureOn the Cusp of a CureIs Asia Pacific Ready for the Precision Era?2 L.E.K.Consulting|On the Cusp of a CureAcknowledgements L.E.K.Consulting would like to acknowledge the contributions of all the Advisory Committee members who have provided critical insights into the development of this report.
3、Specifically,their contributions have guided the assessment of barriers facing the adoption of Precision Era therapies investigated and recommendations to addressing these barriers.NamePositionOrganisation AustraliaDavid Thomas Chief Scientific OfficerOmicoJaala Pulford Chair of the BoardMTPConnectC
4、hristine CockburnCEO Rare Cancers AustraliaChinaBaorong YuProfessor and market access key opinion leaderUniversity of International Business and EconomicsAndy MokHead of ChinaGuardant HealthKevin HuangFounder and presidentChina Organization for Rare Disorders(CORD)Caicun ZhouProfessor and lung cance
5、r key opinion leaderSchool of Medicine,Tongji UniversityJapanTeruyuki KatoriRepresentative Director Specially Appointed ProfessorFuture Institute Wolong,General Incorporated Association Graduate School of Social Sciences,University of HyogoDaisuke SatoProfessorFujita Health universityManabu MutoProf
6、essorKyoto University Graduate School of MedicineMasahiro MiyakeProfessorKyoto University HospitalNaomi SakuraiFounder and CEOCancer Solutions Keisuke ShimizuLeader Lung cancer HER2 HER HERSouth KoreaPaul LeeFormer GMGilead Sciences KoreaJin-Ah KimAdvocate for rare diseasesSeoul National University